@article{ed28e176f4044248a4b666292f0ddf13,
title = "Predicting knee replacement in participants eligible for disease-modifying osteoarthritis drug treatment with structural endpoints",
abstract = "Objective: Evaluate associations between 2-year change in radiographic or quantitative magnetic resonance imaging (qMRI) structural measures, and knee replacement (KR), within a subsequent 7-year follow-up period. Method: Participants from the Osteoarthritis Initiative were selected based on potential eligibility criteria for a disease-modifying osteoarthritis (OA) drug trial: Kellgren–Lawrence grade 2 or 3; medial minimum joint space width (mJSW) ≥2.5 mm; knee pain at worst 4–9 in the past 30 days on an 11-point scale, or 0–3 if medication was taken for joint pain; and availability of structural measures over 2 years. Mean 2-year change in structural measures was estimated and compared with two-sample independent t-tests for KR and no KR. Area under the receiver operating characteristic curve (AUC) was estimated using 2-year change in structural measures for prediction of future KR outcomes. Results: Among 627 participants, 107 knees underwent KR during a median follow-up of 6.7 years after the 2-year imaging period. Knees that received KR during follow-up had a greater mean loss of cartilage thickness in the total femorotibial joint and medial femorotibial compartment on qMRI, as well as decline in medial fixed joint space width on radiographs, compared with knees that did not receive KR. These imaging measures had similar, although modest discrimination for future KR (AUC 0.62, 0.60, and 0.61, respectively). Conclusions: 2-year changes in qMRI femorotibial cartilage thickness and radiographic JSW measures had similar ability to discriminate future KR in participants with knee OA, suggesting that these measures are comparable biomarkers/surrogate endpoints of structural progression.",
keywords = "Cartilage thickness, Future knee replacement, Joint space width, Osteoarthritis, Quantitative MRI, Radiography",
author = "Kwoh, {C. K.} and H. Guehring and A. Aydemir and Hannon, {M. J.} and F. Eckstein and Hochberg, {M. C.}",
note = "Funding Information: CKK, MCH, and MJH have received research funding from Merck KGaA. CKK has received grant funding from Abbvie. CKK and MCH have provided consulting services to Merck KGaA. CKK has provided consulting services to Fidia, Thusane Astellas, Regulus, TLC and Regeneron. HG is a full-time employee of Merck KGaA. AA is a full-time employee of EMD Serono, a business of Merck KGaA, Darmstadt, Germany; FE is CEO/CMO and co-owner of Chondrometrics GmbH, a company providing qMRI analysis services to academic researchers and to industry and has provided consulting services to Merck KGaA, Samumed, Tissuegene, Servier, Galapagos, and Roche. Further, he has received lecture honoraria from Medtronic.The study was supported by Merck KGaA Darmstadt, Germany and EMD Serono Inc., Billerica, MA, USA (a business of Merck KGaA, Darmstadt, Germany). The study sponsors were involved in the study design, collection, analysis and interpretation of data, in writing the manuscript, and in the decision to submit the manuscript for publication. Funding Information: The study was supported by Merck KGaA Darmstadt, Germany and EMD Serono Inc. , Billerica, MA, USA (a business of Merck KGaA, Darmstadt, Germany). The study sponsors were involved in the study design, collection, analysis and interpretation of data, in writing the manuscript, and in the decision to submit the manuscript for publication. Funding Information: CKK, MCH, and MJH have received research funding from Merck KGaA . CKK has received grant funding from Abbvie . CKK and MCH have provided consulting services to Merck KGaA. CKK has provided consulting services to Fidia, Thusane Astellas, Regulus, TLC and Regeneron. HG is a full-time employee of Merck KGaA. AA is a full-time employee of EMD Serono, a business of Merck KGaA, Darmstadt, Germany; FE is CEO/CMO and co-owner of Chondrometrics GmbH, a company providing qMRI analysis services to academic researchers and to industry and has provided consulting services to Merck KGaA, Samumed, Tissuegene, Servier, Galapagos, and Roche. Further, he has received lecture honoraria from Medtronic . Publisher Copyright: {\textcopyright} 2020 Osteoarthritis Research Society International",
year = "2020",
month = jun,
doi = "10.1016/j.joca.2020.03.012",
language = "English (US)",
volume = "28",
pages = "782--791",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "6",
}